1
项与 CART-PSMA-TGFβRDN cell therapy(Tmunity Therapeutics, Inc.) 相关的临床试验A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGFβRDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.
100 项与 CART-PSMA-TGFβRDN cell therapy(Tmunity Therapeutics, Inc.) 相关的临床结果
100 项与 CART-PSMA-TGFβRDN cell therapy(Tmunity Therapeutics, Inc.) 相关的转化医学
100 项与 CART-PSMA-TGFβRDN cell therapy(Tmunity Therapeutics, Inc.) 相关的专利(医药)
100 项与 CART-PSMA-TGFβRDN cell therapy(Tmunity Therapeutics, Inc.) 相关的药物交易